ES3033635T3 - L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer - Google Patents

L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer

Info

Publication number
ES3033635T3
ES3033635T3 ES19839172T ES19839172T ES3033635T3 ES 3033635 T3 ES3033635 T3 ES 3033635T3 ES 19839172 T ES19839172 T ES 19839172T ES 19839172 T ES19839172 T ES 19839172T ES 3033635 T3 ES3033635 T3 ES 3033635T3
Authority
ES
Spain
Prior art keywords
mutation
exon
egfr
region
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19839172T
Other languages
English (en)
Spanish (es)
Inventor
Shinichi Hasako
Takao Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69174561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3033635(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3033635T3 publication Critical patent/ES3033635T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES19839172T 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer Active ES3033635T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018247131 2018-12-28
PCT/JP2019/051377 WO2020138400A1 (en) 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor

Publications (1)

Publication Number Publication Date
ES3033635T3 true ES3033635T3 (en) 2025-08-06

Family

ID=69174561

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19839172T Active ES3033635T3 (en) 2018-12-28 2019-12-27 L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer

Country Status (20)

Country Link
US (2) US20220072000A1 (pl)
EP (1) EP3902548B1 (pl)
JP (1) JP7303303B2 (pl)
KR (1) KR102930628B1 (pl)
CN (1) CN113423403B (pl)
AU (1) AU2019417691B2 (pl)
BR (1) BR112021012687A2 (pl)
DK (1) DK3902548T3 (pl)
ES (1) ES3033635T3 (pl)
FI (1) FI3902548T3 (pl)
HU (1) HUE071862T2 (pl)
IL (1) IL284330B2 (pl)
MX (1) MX2021007852A (pl)
PH (1) PH12021551545A1 (pl)
PL (1) PL3902548T3 (pl)
PT (1) PT3902548T (pl)
SG (1) SG11202106986VA (pl)
TW (1) TWI837266B (pl)
WO (1) WO2020138400A1 (pl)
ZA (1) ZA202104679B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096372B (zh) * 2020-07-09 2024-09-03 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
WO2022055895A1 (en) * 2020-09-08 2022-03-17 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016003247B1 (pt) * 2013-08-22 2022-05-10 Taiho Pharmaceutical Co., Ltd Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
JP6468611B2 (ja) * 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ, インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
WO2018079310A1 (ja) * 2016-10-31 2018-05-03 大鵬薬品工業株式会社 エクソン20挿入変異型egfr選択的阻害剤
PL3677266T3 (pl) * 2017-09-01 2024-07-01 Taiho Pharmaceutical Co., Ltd. Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21

Also Published As

Publication number Publication date
HUE071862T2 (hu) 2025-09-28
DK3902548T3 (da) 2025-07-07
CN113423403A (zh) 2021-09-21
FI3902548T3 (fi) 2025-07-17
PT3902548T (pt) 2025-06-27
BR112021012687A2 (pt) 2021-09-28
AU2019417691B2 (en) 2025-07-10
PL3902548T3 (pl) 2025-07-28
ZA202104679B (en) 2023-12-20
US20220072000A1 (en) 2022-03-10
IL284330B1 (en) 2025-11-01
CN113423403B (zh) 2025-02-18
US20250144103A1 (en) 2025-05-08
KR102930628B1 (ko) 2026-02-25
CA3124750A1 (en) 2020-07-02
WO2020138400A1 (en) 2020-07-02
KR20210110329A (ko) 2021-09-07
PH12021551545A1 (en) 2022-08-15
JP2022522573A (ja) 2022-04-20
IL284330A (en) 2021-08-31
EP3902548B1 (en) 2025-05-28
JP7303303B2 (ja) 2023-07-04
IL284330B2 (en) 2026-03-01
TW202038965A (zh) 2020-11-01
TWI837266B (zh) 2024-04-01
SG11202106986VA (en) 2021-07-29
AU2019417691A1 (en) 2021-07-22
MX2021007852A (es) 2021-08-11
EP3902548A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
EP3533449B1 (en) Selective inhibitor of exon 20 insertion mutant egfr
ES2972895T3 (es) Inhibidor selectivo del EGFR mutante en el exón 18 y/o en el exón 21
US20250144103A1 (en) L718 and/or l792 mutant treatment-resistant egfr inhibitor
CA3124750C (en) L718 and/or l792 mutant treatment-resistant egfr inhibitor
RU2809621C2 (ru) L718 и/или l792 мутантный ингибитор резистентного к лечению egfr
CA3224526C (en) Exon 18 and/or exon 21 mutant egfr selective inhibitor
RU2785657C2 (ru) Селективный ингибитор egfr, имеющего мутацию в экзоне 18 и/или экзоне 21
HK40060754A (en) L718 and/or l792 mutant treatment-resistant egfr inhibitor
HK40060754B (zh) 对l718和/或l792突变型治疗有抗性的egfr抑制剂
HK40033085B (en) Exon 18 and/or exon 21 mutant egfr selective inhibitor
HK40033085A (en) Exon 18 and/or exon 21 mutant egfr selective inhibitor